The Protocol Review and Monitoring System (PRMS) was implemented in 1990 to oversee research involving cancer patients in the facilifies of the institutions that define KCI. The main objectives of the PRMS include the following: 1) review the scientific merit of cancer research protocols;2) ensure prioritizafion of therapeufic cancer protocols according to KCI's scientific priorities;and 3) monitor scienfific proqress. The Protocol Review and Monitoring Committee is composed of a complementary mix of senior and junior investigators from various disciplines, and specialfies, as well as representatives from the Biostatistics Core, nursing and physician extenders, and administrafive support staff from the Clinical Trials Office Core. The members of the committee represent a sufficient size, and breadth of expertise to conduct a critical, fair scienfific review of all clinical research protocols involving cancer patients in the institufions comprising the Cancer Center. The PRMS provides internal oversight of the scientific and research aspects of the cancer trials, in addition to assuring that its clinical resources are engaged to ensure the best practices for scientific endeavors and applicafions. The function of the PRMS is complementary to that ofthe WSU Human Investigations Committee (HIC), which focuses on the protecfion of human subjects. The PRMS is not intended to duplicate or overiap the responsibilifies of the WSU HIC, nor is it intended to perform an audifing or data and safety monitoring function. The PRMS evaluates all cancer clinical trials, whether derived and supported from institutional resources or from industry. However, the PRMS does not duplicate the results of traditional peer review, which includes protocols supported by various NIH mechanisms (e.g., ROIs, UOIs, POIs, UIOs and P50s), and clinical research protocols approved by the NCI's Cancer Therapy Evaluafion Program. Scientific review takes into account the specific rationale, study design, duplication of studies already in progress elsewhere and at the Cancer Center, adequacy of biostafistical input, and feasibility for complefion of the study within a reasonable time frame.

Public Health Relevance

The PRMS provides internal oversight of the scientific aspects of clinical trials at KCI, closely monitoring the scientific merit, scientific priorities, and the scientific progress of KCI's clinical research. The PRMS complements the functions of the IRB, which focuses on protection of human subjects at KCI. Protocols approved by the PRMS for activation are submitted to the IRB for further review.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600880
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$219,665
Indirect Cost
$75,148
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12
Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5
Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7
Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6
Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018
Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202
Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54
Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867
Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84
Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830

Showing the most recent 10 out of 321 publications